INSYS Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From INSYS Therapeutics, Inc.
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.
The US Food and Drug Administration has taken additional steps to ensure mutations of the COVID-19 virus do not negatively impact the efficacy of tests.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Maintaining the positive changes that health care delivery underwent at the height of COVID-19 has been the talk of the health care industries, but will commercial organizations retain their enthusiasm once the pressures of the pandemic abate?
- Drug Delivery
- Other Names / Subsidiaries
- NeoPharm, Inc.
- Fresenius Biotech GmbH
- Neovii Biotech GmbH